Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 168 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hilzenrath DS. Hearing without listening. POGO. Project on Government Oversight 2020:1. [Ref.ID 103824]
2. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
3. Cita con resumen
Pinzani V, Ladhari C. Jeux pathologiques : pas seulement les agonistes dopaminergiques !. BIP Occitanie 2019;26:octubre. [Ref.ID 103198]
4.Enlace a cita original Cita con resumen
Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]
5. Cita con resumen
Healy D. EMA acknowledges persistent sexual dysfunction after SSRIs & SNRIs. Rxisk 20019:11 de junio. [Ref.ID 103130]
7. Cita con resumen
Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]
8.Enlace a cita original Cita con resumen
Plessis L, Gómez A, García N, Cereza G, Figueras A. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia - a restraint to the potentiality for signal detection. Eur J Clin Pharmacol 2017;73:3 de marzo. [Ref.ID 101453]
9. Cita con resumen
Anónimo. Prescribing information sources for healthcare professionals. Drug Ther Bull 2016;54:129-32. [Ref.ID 100943]
10. Cita con resumen
Anónimo. FDA changing advice for prescribing mifepristone. DIA Daily 2016:2. [Ref.ID 100103]
11. Cita con resumen
Anónimo. FDA warns about several safety issues with opioid pain medicines; requires label changes. U.S. Food and Drug Administration 2016:22 de marzo. [Ref.ID 100078]
12.Tiene citas relacionadas Cita con resumen
Bolen SD, Maruthur NM. The safety of incretin based drug treatments for type 2 diabetes. BMJ 2016;352:i801. [Ref.ID 100062]
13. Cita con resumen
Anónimo. Safety information for antipsychotic drug Abilify and risk of certain impulse-control behaviours . Healthy Canadians 2015:2 de noviembre. [Ref.ID 99611]
14. Cita con resumen
Anónimo. Oral diclofenac no longer available OTC. Drug Ther Bull 2015;53:14-7. [Ref.ID 98777]
15. Cita con resumen
Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf 2014;37:897-902. [Ref.ID 98405]
16. Cita con resumen
Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019. [Ref.ID 98190]
17.Enlace a cita original Cita con resumen
Anónimo. FDA adding general warning to testosterone products about potential for venous blood clots. U.S. Food and Drug Administration 2014:19 de junio. [Ref.ID 97716]
18. Cita con resumen
Tatham KC, Patel KP. Why can't all drugs be vegerarian?. BMJ 2014;348:18-20. [Ref.ID 97253]
19. Cita con resumen
Racoosin JA, Roberson DW, Pacanowski MA, Nielsen DR. New evidence about an old drug - Risk with codeine after adenotonsillectomy. N Engl J Med 2013;368:2155-7. [Ref.ID 95602]
20. Cita con resumen
Anónimo. Magnesium sulfate: drug safety communication - Recommendation against prolonged use in pre-term labor . U.S. Food and Drug Administration 2013:30 de mayo. [Ref.ID 95521]
Seleccionar todas
 
 1 a 20 de 168 siguiente >>